What are Travere Therapeutics, Inc.'s profit margins?

Gross margin is 98.6% and operating margin is -10.6%, with a -20.3% net margin.

Where does Travere Therapeutics, Inc.'s income statement data come from?

Every line is extracted from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Travere Therapeutics, Inc. TVTX Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$536.2M+96.0%	$490.73M+110%	$435.83M+114%	$333.87M+87.9%	$273.53M+75.7%
Total cost of revenue	$7.61M-30.3%	$10.34M+33.5%	$10.34M+6.0%	$10.38M+10.2%	$10.92M+24.0%
Gross profit	$528.59M+101%	$480.39M+113%	$425.49M+120%	$323.49M+92.3%	$262.61M+78.8%
Gross margin	98.6%+2.6pp	97.9%+1.2pp	97.6%+2.4pp	96.9%+2.2pp	96%+1.7pp
Research and development	$216.22M+0.6%	$206.01M-5.3%	$210.21M-2.3%	$210M-6.3%	$214.97M-9.0%
Selling, general and administrative	$344.62M+32.4%	$324.78M+23.0%	$292.58M+13.3%	$271.75M+4.4%	$260.31M-1.3%
Total costs & expenses	$593.26M+18.5%	$553.55M-0.6%	$526.96M-6.0%	$506.08M-11.4%	$500.8M-14.5%
Operating income	-$57.06M+74.9%	-$62.82M+80.6%	-$91.13M+74.5%	-$172.21M+56.3%	-$227.26M+47.1%
Operating margin	-10.6%+72.4pp	-12.8%+126pp	-20.9%+155pp	-51.6%+170pp	-83.1%+193pp
Interest expense	$10.19M-9.3%	$10.75M-3.9%	$11.27M+0.8%	$11.3M+0.6%	$11.24M-0.4%
Interest income	$11.51M-26.1%	$12.72M-28.6%	$13.92M-34.2%	$14.45M-38.4%	$15.58M-35.5%
Other income (expense), net	$12.25M+819%	$13.55M+308%	$2.58M-70.1%	$3.11M-70.8%	$1.33M-90.9%
Income before income taxes	-$44.81M+80.2%	-$49.27M+84.6%	-$88.55M+74.6%	-$169.1M+55.9%	-$225.93M+45.6%
Income tax expense	$829K—	$988K—	——	——	——
Net income	——	——	-$88.54M+74.8%	-$169.06M-15.9%	-$226.71M-40.7%
Income from continuing operations	——	——	——	——	——
Diluted earnings per share	——	——	-$1.04+77.1%	-$2.02-7.4%	-$2.79-32.9%
Basic earnings per share	——	——	-$1.03+77.4%	-$2.02-7.4%	-$2.79-32.9%
Weighted-average shares, diluted	372.6M+15.5%	369.1M+18.6%	358.8M+17.0%	334M+9.4%	322.5M+6.2%
Weighted-average shares, basic	359.3M+11.4%	355.7M+14.3%	345.4M+12.6%	334M+9.4%	322.5M+6.2%
Royalty expense	——	——	——	——	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$24.24M+89.3%	-$29.25M+90.9%	-$88.58M+74.6%	-$168.23M-17.1%	-$225.66M-40.3%
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent	-$45.64M+79.8%	-$50.26M+84.3%	-$88.54M+74.6%	-$169M+55.9%	-$225.9M+45.7%
Other income, net (Note 6)	$10.94M+464%	$11.58M+449%	-$71K+94.8%	-$38K+97.5%	-$3.01M-272%
Research and development expense	$216.22M+0.6%	$206.01M-5.3%	$210.21M-2.3%	$210M-6.3%	$214.97M-9.0%
Revenue From Contract With Customer Excluding Assessed Tax	$536.2M+96.0%	$490.73M+110%	$435.83M+114%	$333.87M+87.9%	$273.53M+75.7%
EBIT	-$57.06M+74.9%	-$62.82M+80.6%	-$91.13M+74.5%	-$172.21M+56.3%	-$227.26M+47.1%
EBITDA	$16.09M+109%	-$2.08M+99.3%	-$36.43M+88.5%	-$122.06M+65.4%	-$180.79M+53.4%
EBITDA	$16.09M+109%	-$2.08M+99.3%	-$36.43M+88.5%	-$122.06M+65.4%	-$180.79M+53.4%
EBITDA margin	3%+69.1pp	-0.4%+120pp	-8.4%+147pp	-36.6%+162pp	-66.1%+183pp
EBIT	-$57.06M+74.9%	-$62.82M+80.6%	-$91.13M+74.5%	-$172.21M+56.3%	-$227.26M+47.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Travere Therapeutics, Inc.'s profit margins?: Gross margin is 98.6% and operating margin is -10.6%, with a -20.3% net margin.
Where does Travere Therapeutics, Inc.'s income statement data come from?: Every line is extracted from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.